Once-daily therapies for the treatment of HIV infection

Current HIV/AIDS Reports

Volumn 3, Issue 2, 2006, Pages 86-92

  Tashima, Karen T ^a   Mitty, Jennifer Adelson ^b  

^a MIRIAM HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; TENOFOVIR;

DRUG DOSE REGIMEN; DRUG TOLERABILITY; HALF LIFE TIME; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REVIEW;

ANTI-HIV AGENTS; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 33750381570     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-006-0023-0     Document Type: Review

References (48)

1. Tashima KT, Hogan JW, Gardner LI, et al.: A longitudinal analysis of hospitalization and emergency department use among HIV-infected women reporting protease inhibitor use. Clin Infect Dis 2001, 33:2055-60.
2. Gallant JE: Sidebar: Thoughts on the once-daily-dosing bandwagon (editorial to Hawkins). AIDS Read 2004, 14:336.
3. Paterson DL, Swindells S, Mohr M, et al.: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000, 133:21-30.
4. Weiser SD, Guzman D, Riley ED: Higher rates of viral suppression with nonnucleoside reverse transcriptase inhibitors compared to single protease inhibitors are not explained by better adherence. HIV Clin Trials 2004, 5:278-287.
5. Stone VE, Jordan J, Tolson J, et al.: Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr 2004, 36:808-816.
6. Sherer RD, Path MJ, Da Silva BA, et al.: The importance of potency and durability in HIV patient antiretroviral therapy preferences: A telephone survey. AIDS Patient Care STDS 2005, 19:794-802.
7. Hawkins T: Impact of once-and twice-daily dosing regimens on adherence and overall safety. AIDS Read 2004, 14:320-336.
8. Portsmouth SD, Osorio J, McCormick K, et al.: Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules. HIV Med 2005, 6:185-190.
9. Fairley CK, Permana A, Read TR: Long-term utility of measuring adherence by self-report compared with pharmacy record in a routine clinic setting. HIV Med 2005, 6:366-369.
10. Stenzel MS, McKenzie M, Mitty JA, et al.: Enhancing adherence to HAART: modified directly observed therapy. AIDS Read 2001, 11:317-328.
11. Mitty JA, Macalino GE, Bazerman LB: The use of community-based, modified directly observed therapy for the treatment of HIV-infected persons. J Acquir Immune Defic Syndr 2005, 39:545-550.
12. Jayaweera DT, Kolber MA, Brill M, et al.: Effectiveness and tolerability of a once-daily amprenavir/ritonavir-containing highly active antiretroviral therapy regimen in antiretroviral-naïve patients at risk for nonadherence: 48-week results after 24 weeks of directly observed therapy. HIV Med 2004, 5:364-370.
13. Altice FL, Mezger J, Hodges J, et al.: Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: implications for program replication. Clin Infect Dis 2004, 38(Suppl 15):S376-387.
14. rd Annual Meeting of the Infectious Disease Society of America. San Francisco, CA; October 6-9, 2005.
15. Mitty JA, Mwamburi DM, Macalino GE, et al.: Improved virologic outcomes and less HIV resistance for HAART-experienced substance users receiving modified directly observed therapy (MDOT): Results from a randomized controlled trial. Poster presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5-8, 2006.
16. Back DJ, Burger DM, Flexner CW, Gerber JG: The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: implications for once-daily dosing. J Acquir Immune Defic Syndr 2005, 39:S1-S23. Comprehensive review of NRTI pharmacology and rationale for once-daily dosing.
17. DeJesus E, McCarty D, Farthing CF, et al.: Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naïve adults with HIV infection: a randomized equivalence trial. Clin Infect Dis 2004, 39:411-418.
18. Moyle GJ, Dejesus E, Cahn P, et al.: Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study. J Acquir Immune Defic Syndr 2005, 38:417-425.
19. van Leth F, Phanuphak P, Ruxrungtham K, et al.: Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomized open-label trial, the 2NN Study. Lancet 2004, 363:1253-1263.
20. Clifford DB, Evans S, Yang Y, et al.: Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s). Ann of Intern Med 2005, 143:714-721.
21. Molina JM, Wilkin A, Domingo P: Once-daily vs. twice-daily lopinavir/ritonavir in antiretroviral-naïve patients: 96-week results. Presented at the 3rd IAS conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil; July 24-27, 2005.
22. Cohen C, Elion R, Dejesus E, et al.: 48 week analysis of efficacy and safety of once-daily (QD) abacavir/lamivudine/zidovudine (trizivir) + tenofovir (TDF). Presented at the 45th Interscience Conference of Antimicrobial Agents and Chemotherapy. Washington, DC; December 16-19, 2005.
23. Kumarasamy N, Vallabhaneni S, Flanigan TP, et al.: Rapid viral load suppression following generic highly active antiretroviral therapy in southern Indian HIV-infected patients (research letter). AIDS 2005, 19:625-627.
24. Department of Health and Human Services: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, October 6, 2005. http://AIDSinfo.nih. gov. Accessed January 11, 2006. Updated to provide clinicians with the most current and state-of-the-art treatment information.
25. Gallant JE, Staszewski S, Pozniak AL, et al.: Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naïve patients, a 3-year randomized trial. JAMA 2004, 292:191-201.
26. Gallant JE, DeJesus E, Arribas JR, et al.: Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. New Engl J Med 2006, 354:251-260.
27. Leon A, Mallolas J, Martinez E, et al.: High rate of virological failure in maintenance antiretroviral therapy with didanosine and tenofovir in treatment-experienced patients. AIDS 2005, 19:1695-1697.
28. Barrios A, Negredo E, Domingo P, et al.: Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial. Antivir Ther 2005, 10:825-832.
29. Negredo E, Molto J, Burger D, et al.: Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. AIDS 2004, 18:459-463.
30. Kakuda TN, Anderson PL, Becker SL: CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related. AIDS 2004, 18:2442-2444.
31. Negredo E, Bonjoch A, Paredes R, et al.: Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies. Clin Infect Dis 2005, 41:901-905.
32. Molina JM, Journot V, Morand-Joubert L, et al.: Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-infected adults with viral suppression receiving a protease inhibitor regimen: a randomized trial. J Infect Dis 2005, 191:830-839.
33. DeJesus E, McDonald C, Garcia F, et al.: Effects of switching from fixed dose zidovudine/lamivudine (CBV) to fixed dose tenofovir DF/emtricitabine (TVD): maintenance of virologic suppression and other benefits. Presented at the 45th Annual Meeting of the Interscience Conference of Antimicrobial Agents and Chemotherapy. Washington, DC; December 16-19, 2005.
34. Gallant JE, Rodriguez AE, Weinberg WG, et al.: Early virologic nonresponse to tenofovir, abacavir, and lamuvudine in HIV-infected antiretroviral-naïve subjects. J Infect Dis 2005, 192:1921-1930.
35. Khanlou H, Yeh V, Guyer B, Farthing C: Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naïve HIV-infected patients. AIDS Patient Care STDS 2005, 19:135-140.
36. Landman R, Peytavin G, Descamps D, et al.: Low genetic barrier to resistance is a posible cause of early virologic failures in once-daily regimen of abacavir, lamivudine, and tenofovir: the TONUS study. Presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8-11, 2004.
37. Jemsek J, Hutcherson P, Harper E: Poor virologic responses and early emergence of resistance in treatment naïve, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine and tenofovir DF. Presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8-11, 2004.
38. Leon A, Martinez E, Mallolas J, et al.: Early virological failure in treatment-naïve HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine. AIDS 2005, 19:213-215.
39. Maitland D, Moyle G, Hand I, et al.: Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial. AIDS 2005, 19:1183-1188.
40. Kuritzkes DR: Less than the sum of its parts: failure of a tenofovir-abacavir-lamivudine triple-nucleoside regimen [editorial commentary]. J Infect Dis 2005, 192:1867-1868.
41. Cardiello P, Srasuebkul P, Hassink E, et al.: The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy. HIV Med 2005, 6:122-128.
42. Harris M, Press N, Thorne A, et al.: Results of simplified protease inhibitor trial: antiviral effect of once daily saquinavir SCC plus ritonavir vs. twice daily indinavir plus ritonavir (SPRINT). Presented at the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 22-25, 2005.
43. Johnson M, Grinsztejn B, Rodriguez C, et al.: Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005, 19:685-694.
44. Murphy RL, Schurmann D, Beard A, et al.: Potent anti-HIV-1 activity of Reverset following 10 days of monotherapy in treatment-naïve individuals. Presented at the XV International AIDS Conference. Bangkok, Thailand; July 11-16, 2004.
45. Collins P, Shiveley L, Anderson G, et al.: Analysis of the genotypes of viruses isolated from patients after 10 days monotherapy with SPD754. Presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8-11, 2004.
46. Goebel F, Yakovlev A, Pozniak A, et al.: TMC278: potent anti-HIV activity in antiretroviral therapy-naïve patients. Presented at the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 22-25, 2005.
47. Lalezari J, Thompson M, Kumar P, et al.: Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults. AIDS 2005, 19:1443-1448.
48. Beatty G, Lalezari J, Eron J, et al.: Safety and antiviral activity of PA-457, the first-in-class maturation inhibitor, in a 10-day monotherapy study in HIV-1 infected patients. Presented at the 45th Annual Meeting of the Interscience Conference of Antimicrobial Agents and Chemotherapy. Washington, DC; December 16-19, 2005.